These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 33842191)

  • 1. Computational screening of FDA approved drugs of fungal origin that may interfere with SARS-CoV-2 spike protein activation, viral RNA replication, and post-translational modification: a multiple target approach.
    Singh R; Gautam A; Chandel S; Sharma V; Ghosh A; Dey D; Roy S; Ravichandiran V; Ghosh D
    In Silico Pharmacol; 2021; 9(1):27. PubMed ID: 33842191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach.
    Sabarimurugan S; Purushothaman I; Swaminathan R; Dharmarajan A; Warrier S; Kothandan S
    Acta Virol; 2021; 65(2):160-172. PubMed ID: 34130467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hybrid drug-screening strategy identifies potential SARS-CoV-2 cell-entry inhibitors targeting human transmembrane serine protease.
    Feng Y; Cheng X; Wu S; Mani Saravanan K; Liu W
    Struct Chem; 2022; 33(5):1503-1515. PubMed ID: 35571866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential protease inhibitors and their combinations to block SARS-CoV-2.
    Abhinand CS; Nair AS; Krishnamurthy A; Oommen OV; Sudhakaran PR
    J Biomol Struct Dyn; 2022 Feb; 40(2):903-917. PubMed ID: 32924827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational insights into binding mechanism of drugs as potential inhibitors against SARS-CoV-2 targets.
    Arooj M; Shehadi I; Nassab CN; Mohamed AA
    Chem Zvesti; 2022; 76(1):111-121. PubMed ID: 34483461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A computational approach to drug repurposing against SARS-CoV-2 RNA dependent RNA polymerase (RdRp).
    Ribaudo G; Ongaro A; Oselladore E; Zagotto G; Memo M; Gianoncelli A
    J Biomol Struct Dyn; 2022 Feb; 40(3):1101-1108. PubMed ID: 32948103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
    Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
    J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applying polypharmacology approach for drug repurposing for SARS-CoV2.
    Jamir E; Sarma H; Priyadarsinee L; Nagamani S; Kiewhuo K; Gaur AS; Rawal RK; Murugan NA; Subramanian V; Sastry GN
    J Chem Sci (Bangalore); 2022; 134(2):57. PubMed ID: 35498548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational analysis in international isolates and drug repurposing against SARS-CoV-2 spike protein: molecular docking and simulation approach.
    Pulakuntla S; Lokhande KB; Padmavathi P; Pal M; Swamy KV; Sadasivam J; Singh SA; Aramgam SL; Reddy VD
    Virusdisease; 2021 Dec; 32(4):690-702. PubMed ID: 34307771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Searching for target-specific and multi-targeting organics for Covid-19 in the Drugbank database with a double scoring approach.
    Murugan NA; Kumar S; Jeyakanthan J; Srivastava V
    Sci Rep; 2020 Nov; 10(1):19125. PubMed ID: 33154404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy.
    Shamsi A; Mohammad T; Anwar S; AlAjmi MF; Hussain A; Rehman MT; Islam A; Hassan MI
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32441299
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Gurung AB
    Gene Rep; 2020 Dec; 21():100860. PubMed ID: 32875166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repurposing FDA approved drugs as possible anti-SARS-CoV-2 medications using ligand-based computational approaches: sum of ranking difference-based model selection.
    De P; Kumar V; Kar S; Roy K; Leszczynski J
    Struct Chem; 2022; 33(5):1741-1753. PubMed ID: 35692512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
    Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
    Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening.
    de Oliveira OV; Rocha GB; Paluch AS; Costa LT
    J Biomol Struct Dyn; 2021 Jul; 39(11):3924-3933. PubMed ID: 32448085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico studies of Potency and safety assessment of selected trial drugs for the treatment of COVID-19.
    Adegbola PI; Fadahunsi OS; Adegbola AE; Semire B
    In Silico Pharmacol; 2021; 9(1):45. PubMed ID: 34312587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19).
    De Vita S; Chini MG; Lauro G; Bifulco G
    RSC Adv; 2020 Nov; 10(67):40867-40875. PubMed ID: 35519188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors.
    Kalhotra P; Chittepu VCSR; Osorio-Revilla G; Gallardo-Velazquez T
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33578831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.